Novavax, Inc.

Novavax, Inc.

NVAX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.3B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novavax, Inc.Novavax, Inc.-18.5-35%4.3-1.3
$8.00

Target Price by Analysts

6.2% downsideNovavax Target Price DetailsTarget Price
$24.78

Current Fair Value

190.7% upside

Undervalued by 190.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.30 Billion
Enterprise Value$1.37 Billion
Earnings per Share$2.72
Beta2.72
Outstanding Shares164,924,000

Return

Return on Equity35.38%ROE
Return on Assets-8.64%
Return on Invested Capital-5.11%

Valuation & Multiples

P/E Ratio-18.53P/E Ratio
PEG21.93PEG
Price to Sales4.26Price to Sales
Price to Book Ratio-4.26Price to Book Ratio
Enterprise Value to Revenue3.32
Enterprise Value to EBIT-48.01
Enterprise Value to Net Income-18
Total Debt to Enterprise0.21
Debt to Equity-1.35Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
-$0.19
Est. -$0.35
Revenue
$68.30 M
Est. $50.42 M

Next Earnings Call

Expected Date
February 25, 2027
EPS Estimate
$0.54
Consensus analyst estimate
Revenue Estimate
$216.00 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.41, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.4105▼ 80.79%
Total Calls1,801,363▼ 62.66%
Total Puts739,500▼ 87.42%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %51.79%▼ 20.95%
Total Invested$921.24M▼ 17.63%
Investors Holding211▼ 88.00%

About Novavax, Inc.

749 employees
CEO: Stanley Erck

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxov...

Novavax Insider Information FAQ

Stockcircle tracks 5 top investors with a current 13F position in Novavax. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.